Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
SURMOUNT-1 and STEP-1: Obesity-Specific Trials SURMOUNT-1 (Tirzepatide for Obesity, NEJM 2022): At the maximum 15 mg dose, participants without diabetes lost an average of 22.5% of their body weight over 72 weeks approximately 51 lbs for a 225-lb person
State medical boards and NP boards dont restrict metabolic medications
PCPs Cautious with GLP-1 Prescriptions Despite increasing patient demand, PCPs remain generally cautious when prescribing GLP-1 medications
The physical act of chewing activates the parotid glands and triggers increased salivary output
26 Lifestyle-induced weight loss of 710% can improve MASH with fewer risk factors, and more than 10% can be beneficial for fibrosis
Recommended Use: Helps support fat metabolism and delay fatigue during physical activity
.webp)
